Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-866 perioperative pembrolizumab plus neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer
2022-501970-20-01Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in bladder cancer comparing Pembrolizumab + neoadjuvant gemcitabine/cisplatin with Placebo + neoadjuvant gemcitabine/cisplatin (2 arms). Primary endpoint: Event-Free Survival (EFS). Started Jan 2024; status: completed.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2022-501970-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501970-20-01.